Navigation Links
AtheroNova Announces Milestone Filing of IND in Russian Federation
Date:11/13/2012

IRVINE, Calif., Nov. 13, 2012 /PRNewswire/ -- AtheroNova Inc. (OTCBB: AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and to improve lipid profiles in humans, today announced that its Russian licensing partner OOO CardioNova has formally submitted its Investigational New Drug (IND) application with the Ministry of Health of the Russian Federation (Minzdrav).  This filing is the first step in the process of obtaining approval in Russia to conduct the Phase 1 human clinical trials in the centers selected by CardioNova.  It is expected that the approval of the application will be granted by the Ministry early in 2013 and the Phase 1 will commence shortly thereafter.

"We are extremely gratified in achieving this milestone in our path to human trials of AHRO-001," said AtheroNova CEO Thomas W. Gardner.  "OOO CardioNova has diligently pushed this filing forward with the utmost urgency and we want to thank them for their efforts to complete this major step in the process of clinical development of AHRO-001.  We continue to work aggressively toward our mutual goal of commencement of Phase 1 clinical trials within the next 90 days."

"We are pleased to have such a tremendous business partner in AtheroNova as we continue to endeavor toward approval of the Phase 1 protocol by the Ministry of Health," commented Dr. Alexey Eliseev, managing partner of Maxwell Biotech Group, OOO CardioNova's parent company. "Our objective is to work diligently with the Ministry of Healthcare for approval of our submission while making final preparations for the commencement of pre-screening and ultimately Phase 1 clinical trials in our Russian study centers.  We are excited with the prospect of initiating clinical trials in anticipation of potentially addressing one of the major health risks facing Russia, and throughout the world.

About AHRO-001

AHRO-001 is AtheroNov
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AtheroNova Receives Notice of Allowance for Its US Patent Application 12/024,908
2. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
3. Remedy Informatics Announces Growth Capital Investment from Merck Global Health Innovation Fund
4. RPS Announces Jonathan M. Fishbein, MD as Executive Vice President and Chief Medical Officer
5. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
6. Developmental Disabilities Software announces Safe Harbor Self-Certification Compliance
7. Hologic Announces Fourth Quarter and Fiscal 2012 Operating Results
8. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
9. Valeritas Announces The Publication Of A Retrospective Analysis Of Patient-Reported Data On The V-Go In The Current Issue Of Endocrine Practice
10. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
11. 3SBio Inc. Announces Unaudited Third Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... TAMPA, Fla. , Sept. 17, 2014   ... announced today that Business Insurance magazine has ... Insurance" distinction for the third year in a row. ... joint effort of Business Insurance  and the Best ... evaluation, is open to all publicly or privately-held insurance ...
(Date:9/17/2014)... ANGELES and LEIPZIG, Germany ... today announced that it has entered into an ... the development of antibody-based imaging agents to image ... "Our collaboration with Novotectid expands ImaginAb,s capability to precisely ... immune-oncology and autoimmune disease areas. The ability to ...
(Date:9/17/2014)... PALO ALTO, Calif. , Sept. 17, 2014 /PRNewswire/ ... of the Company,s Phase 2 clinical program of NP001 ... Lou Gehrig,s disease) are being highlighted today ... of the ALS Research Group , being held in ... According to a  post hoc  analysis, administration of a ...
Breaking Medicine Technology:myMatrixx Honored with "Best Places to Work in Insurance" Award 2ImaginAb Expands ImmunoPET Pipeline to Include CD4+ T-Cell Imaging 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
... Reportlinker.com announces that a new market research report ... Drug Delivery in Central Nervous System Diseases - ... The delivery of drugs ... in the treatment of neurological disorders. Drugs may ...
... Robbins & Myers, Inc. (NYSE: ... its Romaco businesses to a group of funds led ... investment firm.  Total consideration was approximately euro 65 million ... and euro 4 million of assumed liabilities and is ...
Cached Medicine Technology:Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 2Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 3Reportlinker Adds Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies 4
(Date:9/17/2014)... (PRWEB) September 17, 2014 As kinship ... for children who cannot live with their parents, emphasis ... to continue to enhance services and supports for kinship ... America’s (CWLA) National Kinship Care Conference is being held ... knowledge of best practice, policy, program and service development ...
(Date:9/17/2014)... Final Cut Pro X plugin developers have ... Pixel Film Studios. , “ProBlue 5k is a compilation of ... to epic,” said Christina Austin, CEO of Pixel Film Studios. ... a definite game changer.” , ProBlue 5k is the ultimate ... filmmaker ! This footage compilation of over 100 anamorphic flares ...
(Date:9/17/2014)... A new, first-of-its-kind research study was announced today ... lifestyle can impact long-term wellness and contribute to ... Prevention Research Center and funded through a $10 ... Institute Wellness Fund, WELL aims to identify lifestyle ... their health and wellness as they age. WELL ...
(Date:9/17/2014)... 17, 2014 In its latest blog post, ... believes that having family close by during a stay in ... the process is successful, is highlighting a member of the ... the lives of addicts across the country and around the ... can reduce the blood pressure, heart rate, and stress levels ...
(Date:9/17/2014)... manipulation these sound like the ideas of ... are components of an exciting new approach to ... models of metastatic prostate cancer, scientists at Virginia ... Molecular Medicine and Johns Hopkins Medical Institutions have ... that could revolutionize doctors, ability to see tumors ...
Breaking Medicine News(10 mins):Health News:Arizona’s Children Association Kinship Service Providers Invited to Present at the CWLA National Conference 2Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:First-ever research study examines impacts of diet and lifestyle on healthy aging 2Health News:Latest Best Drug Rehabilitation Blog Post Highlights How Dogs are Helping Addicts Recover 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 2Health News:New non-invasive technique could revolutionize the imaging of metastatic cancer 3
... July 1 AlphaMed Press, co-publisher of the journal ... stem cells and regenerative medicine, has promoted Miodrag Stojkovic ... is Deputy Director of the Prince Felipe Research Centre ... Spain. He led the team that first announced derivation ...
... ... two winners of their 2009 North American Grant Program. Exiqon had recently announced ... non-profit institutions across North America, engaged in microRNA research. , ... (PRWEB) July 1, 2009 -- Exiqon A/S ...
... ... the past 30 years, The Free Choice Foundation is a newly established grassroots organization ... with regards to healthcare. , ... Tokyo, Japan (PRWEB) July 1, 2009 -- Based on the spirit of ...
... Also recommends dosing limits for OTC products that contain ... liver damage. , TUESDAY, June 30 (HealthDay News) ... combine acetaminophen with an opiate narcotic, should be banned, ... like Tylenol or Excedrin, should be lowered, a U.S. ...
... Disease , , WASHINGTON, June 30 Today Lung ... Cancer illustrating again the devastating toll caused by lung cancer. ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO ) ... analyzes the most recent available data from the National Institutes of ...
... Andrew Ordon, co-host of the syndicated talk show The ... a non-invasive skin contouring procedure, at his state-of-the-art surgical facilities ... is the perfect option for someone who wants to look ... explains Ordon. "There is little to no downtime with this ...
Cached Medicine News:Health News:STEM CELLS Promotes Miodrag Stojkovic to Editor 2Health News:Exiqon Announces 2009 North American Grant Award Winners 2Health News:Exiqon Announces 2009 North American Grant Award Winners 3Health News:Newly Launched Free Choice Foundation Attempts Rescue of Japan's Private Heath Care Network 2Health News:Newly Launched Free Choice Foundation Attempts Rescue of Japan's Private Heath Care Network 3Health News:FDA Panel Urges Ban on Vicodin, Percocet 2Health News:FDA Panel Urges Ban on Vicodin, Percocet 3Health News:FDA Panel Urges Ban on Vicodin, Percocet 4Health News:Lung Cancer Alliance Releases Updated 2009 Facts About Lung Cancer 2
... The Eppendorf Reference Series 2000 Pipette ... smooth stroke, a compact and robust design, ... button is used to operate the measuring ... the tip. Product features:Eppendorf "pipette/tip" system ensures ...
50L...
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...
Medicine Products: